Inflazome

Start-up Biotech dedicated to improving lives by delivering new medicines that stop #inflammation by inhibiting #NLRP3 inflammasome

[Shake It Up Australia @shakeitupaust]

Inflazome announces acquisition by Roche. Inflazome is developing orally available NLRP3 inflammasome inhibitors. One of the companies molecules is Inzomelid, a brain-penetrant drug for the treatment of neurodegenerative diseases such as Parkinson’s. https://t.co/obr2R2GPJX

[KTI Connect @KTIconnect]

Diarmuid O'Brien explains how @inflazome's recent acquisition by Roche shows how Irish science can work productively with entrepreneurs and venture capitalists.

He imagines the possible future @inflazome's in an innovation district #KT

Read more at https://t.co/gSUJQdQULH

[Inflazome @inflazome]

Hear, hear!

[Trinity Innovation KnEx @TCD_Innovation]

Thoughts from @tcddublin Provost @pjprendergast on $448m acquistion of joint @TrinityResInnov / @UniQuestUQ company @inflazome :

[Roche @Roche]

Roche's William Pao on our recent acquisition of Ireland-based biotech company Inflazome. Check out the press release here 👉 https://t.co/mchXItO58E

[Trinity College Dublin @tcddublin]

Trinity spinout, @inflazome, Founded by Professor @laoneill111 has secured orphan drug designation for Inzolemid, a therapy that it is developing. Read about it here: https://t.co/EvGmQI4weu #TrinityResearch #Enterprise #InspiringGenerations

[Inflazome @inflazome]

@sarahcorcor @IrishTimesBiz An important part, @sarahcorcor Patient validation was key!

[Inflazome @inflazome]

@KTIconnect @TrinityResInnov You mean @inflazome? 😀

[Inflazome @inflazome]

Really enjoyed this read, Ryan. Great outcome today.

[Ryan Cross the Science Boss @RLCscienceboss]

This morning @inflazome, a company developing #NLRP3 #inflammasome inhibitors, said that @Roche would acquire it for €380 million. For background one these potential 'pipeline-in-a-pill' drugs, check out my @cenmag cover story from earlier this year: https://t.co/U8PQ03LcDf

[Silicon Republic @siliconrepublic]

Just four years after it was founded, @inflazome has been snapped up by @Roche in a multimillion-euro deal. https://t.co/4iWm8AeE2C

[BioWorld @BioWorld]

@Roche acquiring @Inflazome for $448M up front https://t.co/PSeArrnBbt

[pressetext.com @pressetext]

#Roche übernimmt #Inflazome für 380 Mio. Euro. Irisches Pharmaunternehmen hat sich unter... https://t.co/oZ2tJ4Bt4I

[Inflazome @inflazome]

We are delighted to join the @Roche family and continue to develop our #NLRP3 inhibitors together.

[Roche @Roche]

Roche's William Pao on our recent acquisition of Ireland-based biotech company Inflazome. Check out the press release here 👉 https://t.co/mchXItO58E

[Trinity Innovation KnEx @TCD_Innovation]

Swiss drug giant Roche pays €380m for @tcddublin spinout biotech Inflazome https://t.co/rbAl9FdnqG

[Inflazome @inflazome]

We could not have done this without Fountain's support and guidance over the years. With thanks!

[Fountain Healthcare Partners @fhpartners]

Congrats to the @inflazome team on the successful sale of the company to @Roche.
#inflammasome #NLRP3

https://t.co/V3KyzPfIyi

[EOY Ireland @EOYIreland]

Another great news story for one of our 2020 Finalist's - Matt Cooper of @inflazome who have been bought by swiss drug giant Roche for €380m.

https://t.co/Fb6ui9aULb

[Will Goodbody @willgoodbody]

BREAKING: Dublin and Cambridge based @inflazome, the four year old biotech firm set up by @laoneill111 and Prof Matt Cooper, has been sold to Roche for €380m plus further possible additional milestone payments.

[Inflazome @inflazome]

We are delighted to announce Inflazome's acquisition by Roche. We look forward to working together to develop our #NLRP3 inflammasome inhibitors for patients with #inflammatory diseases.

https://t.co/W6lfGuWJrv

[Trinity Innovation KnEx @TCD_Innovation]

Trinity Campus Company @inflazome amongst the finalists

[EOY Ireland @EOYIreland]

@IrishTimes profiles our next four EOY 2020 Finalists. We learn more about @AnaBio_Tech @Pharmapod @workvivo @inflazome
#EOY2020 #Business #Entrepreneurship

https://t.co/dYyU2YkYRn

[Inflazome @inflazome]

We are delighted to announce that the FDA has granted Orphan Drug Designation for Inflazome’s Inzomelid for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) - a very important milestone for for the company and patients!

Read more here:
https://t.co/4C8ArloZgG